Can the external masculinization score predict the success of genetic testing in 46,XY DSD?

R. Su, M. Adam, Linda A. Ramsdell, P. Fechner, M. Shnorhavorian
{"title":"Can the external masculinization score predict the success of genetic testing in 46,XY DSD?","authors":"R. Su, M. Adam, Linda A. Ramsdell, P. Fechner, M. Shnorhavorian","doi":"10.3934/genet.2015.2.163","DOIUrl":null,"url":null,"abstract":"Abstract Genetic testing is judiciously applied to individuals with Disorders of Sex Development (DSD) and so it is necessary to identify those most likely to benefit from such testing. We hypothesized that the external masculinization score (EMS) is inversely associated with the likelihood of finding a pathogenic genetic variant. Patients with 46,XY DSD from a single institution evaluated from 1994–2014 were included. Results of advanced cytogenetic and gene sequencing tests were recorded. An EMS score (range 0–12) was assigned to each patient according to the team's initial external genitalia physical examination. During 1994–2011, 44 (40%) patients with 46,XY DSD were evaluated and underwent genetic testing beyond initial karyotype; 23% (10/44) had a genetic diagnosis made by gene sequencing or array. The median EMS score of those with an identified pathogenic variant was significantly different from those in whom no confirmed genetic cause was identified [median 3 (95% CI, 2–6) versus 6 (95% CI, 5–7), respectively (p = 0.02)], but limited to diagnoses of complete or partial androgen insensitivity (8/10) or 5α-reductase deficiency (2/10). In the modern cohort (2012–2014), the difference in median EMS in whom a genetic cause was or was not identified approached significance (p = 0.05, median 3 (95% CI, 0–7) versus 7 (95% CI, 6–9), respectively). When all patients from 1994–2014 are pooled, the EMS is significantly different amongst those with compared to those without a genetic cause (median EMS 3 vs. 6, p < 0.02). We conclude that an EMS of 3 or less may indicate a higher likelihood of identifying a genetic cause of 46,XY DSD and justify genetic screening, especially when androgen insensitivity is suspected.","PeriodicalId":43477,"journal":{"name":"AIMS Genetics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIMS Genetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3934/genet.2015.2.163","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Abstract Genetic testing is judiciously applied to individuals with Disorders of Sex Development (DSD) and so it is necessary to identify those most likely to benefit from such testing. We hypothesized that the external masculinization score (EMS) is inversely associated with the likelihood of finding a pathogenic genetic variant. Patients with 46,XY DSD from a single institution evaluated from 1994–2014 were included. Results of advanced cytogenetic and gene sequencing tests were recorded. An EMS score (range 0–12) was assigned to each patient according to the team's initial external genitalia physical examination. During 1994–2011, 44 (40%) patients with 46,XY DSD were evaluated and underwent genetic testing beyond initial karyotype; 23% (10/44) had a genetic diagnosis made by gene sequencing or array. The median EMS score of those with an identified pathogenic variant was significantly different from those in whom no confirmed genetic cause was identified [median 3 (95% CI, 2–6) versus 6 (95% CI, 5–7), respectively (p = 0.02)], but limited to diagnoses of complete or partial androgen insensitivity (8/10) or 5α-reductase deficiency (2/10). In the modern cohort (2012–2014), the difference in median EMS in whom a genetic cause was or was not identified approached significance (p = 0.05, median 3 (95% CI, 0–7) versus 7 (95% CI, 6–9), respectively). When all patients from 1994–2014 are pooled, the EMS is significantly different amongst those with compared to those without a genetic cause (median EMS 3 vs. 6, p < 0.02). We conclude that an EMS of 3 or less may indicate a higher likelihood of identifying a genetic cause of 46,XY DSD and justify genetic screening, especially when androgen insensitivity is suspected.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
外部男性化评分能否预测46,xy DSD基因检测的成功?
基因检测被明智地应用于患有性发育障碍(DSD)的个体,因此有必要确定那些最有可能从这种检测中受益的个体。我们假设外部男性化评分(EMS)与发现致病遗传变异的可能性呈负相关。纳入1994-2014年来自单一机构评估的46,xy DSD患者。记录先进的细胞遗传学和基因测序测试结果。根据团队最初的外生殖器体检结果,对每位患者进行EMS评分(范围0-12)。1994-2011年间,44例(40%)46,XY型DSD患者接受了除初始核型外的基因检测;23%(10/44)的患者通过基因测序或基因阵列进行基因诊断。确定致病变异的患者的EMS中位数评分与未确定遗传原因的患者有显著差异[中位数分别为3 (95% CI, 2-6)和6 (95% CI, 5-7) (p = 0.02)],但仅限于完全或部分雄激素不敏感(8/10)或5α-还原酶缺乏症(2/10)的诊断。在现代队列(2012-2014)中,遗传原因确定或未确定的中位EMS差异接近显著性(p = 0.05,中位3 (95% CI, 0-7)与中位7 (95% CI, 6-9))。当合并1994-2014年的所有患者时,与没有遗传原因的患者相比,EMS显着不同(EMS中位数为3比6,p < 0.02)。我们的结论是,EMS为3或更低可能表明更有可能确定遗传原因46xy DSD,并证明遗传筛查是合理的,特别是当怀疑雄激素不敏感时。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
AIMS Genetics
AIMS Genetics GENETICS & HEREDITY-
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
Evidence for novel epigenetic marks within plants. The roles of genes in the bitter taste. A robust circular RNA-based prognostic signature for postoperative recurrence in stage II/III colon cancer. Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety PDE4B gene polymorphism in Russian patients with panic disorder
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1